OTCMKTS:MYCOF

Mydecine Innovations Group - MYCOF Stock Forecast, Price & News

$0.38

-0.03 (-7.32%)

(As of 03/24/2023 12:00 AM ET)

Add

Compare

Today's Range: $0.36
▼
$0.44
50-Day Range: $0.36
▼
$0.47
52-Week Range: $0.05
▼
$5.00

Volume: 62,681 shs
Average Volume: 9,665 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Mydecine Innovations Group (OTCMKTS:MYCOF) Stock

Mydecine Innovations Group, Inc. operates as a life sciences company dedicated to the development and commercialization of adaptive pathway medicines, natural health products and digital health solutions. It encompasses three companies: Mindleap Health, Mydecine Health Sciences, and NeuroPharm Inc. The Mindleap Health is an advanced digital health platform that helps people connect with mental health specialists who can empower them to thrive and develop habits for a healthy mind. The Mydecine Health Sciences is a vertically integrated company developing novel fungtional mushroom products and psychedelic medicines for healthy and vulnerable populations. The NeuroPharm is developing a unique and proprietary set of pharmaceutical and natural health products addressing mental wellness in vulnerable populations. The company was founded by Parente Carman on September 27, 2013 and is headquartered in Vancouver, Canada.

Receive MYCOF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mydecine Innovations Group and its competitors with MarketBeat's FREE daily newsletter.

MYCOF Stock News Headlines

March 6, 2023 | finance.yahoo.com

Mydecine Announces Debt Settlements

January 27, 2023 | seekingalpha.com

KAVL Kaival Brands Innovations Group, Inc.

March 26, 2023 | Weiss Ratings (Ad)

Bank Accounts: Frozen!

In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!

December 13, 2022 | benzinga.com

Psychedelic Company Sale: Mydecine Gets Over $2.5M For Wholly-Owned Tech Subsidiary Business

November 15, 2022 | msn.com

Mydecine's Q3 Financials & Update, Sustained Target On Smoking Cessation For Next 12 Months

November 15, 2022 | finanznachrichten.de

Mydecine Innovations Group Inc.: Mydecine Reports Financial Results for the Third Quarter of Fiscal Year 2022

November 15, 2022 | finance.yahoo.com

Mydecine Reports Financial Results for the Third Quarter of Fiscal Year 2022

November 15, 2022 | finance.yahoo.com

Mydecine Reports Financial Results for the Third Quarter of Fiscal Year 2022

March 26, 2023 | Weiss Ratings (Ad)

Bank Accounts: Frozen!

September 23, 2022 | finance.yahoo.com

MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT AND WELCOMES NEW CFO

September 1, 2022 | finance.yahoo.com

Mydecine Innovations Group Signs a Letter of Intent to Sell its Wholly-Owned Subsidiary, Mindleap Health Inc.

August 19, 2022 | finance.yahoo.com

Mydecine Innovations Group Announces Private Placement; Interim Changes to Management and Board of Directors

August 17, 2022 | seekingalpha.com

Mydecine Innovations Group GAAP EPS of -C$0.35

August 16, 2022 | finance.yahoo.com

Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2022

August 12, 2022 | finance.yahoo.com

MYDECINE INNOVATIONS GROUP ANNOUNCES RESIGNATION OF DIRECTORS

June 17, 2022 | finance.yahoo.com

U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

June 9, 2022 | finance.yahoo.com

Mydecine Provides Company Update; Welcomes New Board Member

May 27, 2022 | proactiveinvestors.com

Mydecine Innovations closes 'best efforts' overnight marketed offering for aggregate gross proceeds of $2,814,199.50

May 27, 2022 | finance.yahoo.com

Mydecine Announces Closing of Overnight Marketed Public Offering of Units

May 20, 2022 | proactiveinvestors.com

Mydecine announces overnight marketed public offering of units

May 19, 2022 | proactiveinvestors.com

Mydecine Innovations Group set to raise up to $4M in previously announced overnight public offering

May 17, 2022 | seekingalpha.com

Mydecine Innovations Group GAAP EPS of -$1.20 misses by $0.41

April 29, 2022 | benzinga.com

MYDECINE INNOVATIONS GROUP FILES PROSPECTUS...

April 27, 2022 | finance.yahoo.com

MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT

April 14, 2022 | msn.com

Mydecine Announces 1-for-50 Reverse Stock Split

April 13, 2022 | seekingalpha.com

Mydecine Innovations Group announces 1-for-50 reverse stock split

April 1, 2022 | proactiveinvestors.com.au

Mydecine ends FY2021 with C$1.5M in cash to help propel mental health treatment initiatives in 2022

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MYCOF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mydecine Innovations Group and its competitors with MarketBeat's FREE daily newsletter.

MYCOF Company Calendar

Last Earnings: 11/16/2021
Today: 3/25/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:MYCOF
CUSIP: N/A
CIK: N/A
Web: www.mydecine.com
Phone: (813) 871-3936
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Key Executives

David Joshua Bartch
Chairman, President & Chief Executive Officer

Damon Michaels
Chief Operating Officer

John Charles Ross
Chief Financial Officer

Robert Roscow
Director & Chief Science Officer

Rakesh Jetly
Chief Medical Officer

Key Competitors

View All Competitors

MYCOF Stock - Frequently Asked Questions

How have MYCOF shares performed in 2023?: Mydecine Innovations Group's stock was trading at $0.43 at the beginning of 2023. Since then, MYCOF shares have decreased by 11.6% and is now trading at $0.38.
View the best growth stocks for 2023 here.
Are investors shorting Mydecine Innovations Group?: Mydecine Innovations Group saw a decline in short interest in the month of February. As of February 28th, there was short interest totaling 300 shares, a decline of 50.0% from the February 13th total of 600 shares. Based on an average trading volume of 25,000 shares, the days-to-cover ratio is presently 0.0 days.
View Mydecine Innovations Group's Short Interest.
How were Mydecine Innovations Group's earnings last quarter?: Mydecine Innovations Group Inc. (OTCMKTS:MYCOF) issued its quarterly earnings results on Tuesday, November, 16th. The company reported ($1.00) EPS for the quarter, missing analysts' consensus estimates of ($0.50) by $0.50.
When did Mydecine Innovations Group's stock split?: Mydecine Innovations Group shares reverse split before market open on Thursday, April 21st 2022. The 1-50 reverse split was announced on Thursday, April 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What is Mydecine Innovations Group's stock symbol?: Mydecine Innovations Group trades on the OTCMKTS under the ticker symbol "MYCOF."
How do I buy shares of Mydecine Innovations Group?: Shares of MYCOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Mydecine Innovations Group's stock price today?: One share of MYCOF stock can currently be purchased for approximately $0.38.
How can I contact Mydecine Innovations Group?: Mydecine Innovations Group's mailing address is 789 West Pender Street, Vancouver, BC V6C. The official website for the company is www.mydecine.com. The company can be reached via phone at (813) 871-3936.

This page (OTCMKTS:MYCOF) was last updated on 3/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial